Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,127.20
(
0.47%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
98.69
(
-1.95%
)
Bitcoin
74,217.77
(
0.37%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 116762

Monday, 03/21/2011 9:55:59 PM

Monday, March 21, 2011 9:55:59 PM

Post# of 257253

Does $2.7B [Leerink Swann] estimate for Copaxone take into account of generic from NVS/MNTA?

I don’t know how Leerink arrived at its $2.7B projection. Copaxone is selling at an annualized rate of $3.8B ($2.6B in the US). A single generic version in the US—which is all there will ever be (IMO)—is not going to make much difference in the average selling price or the total Copaxone sales for the branded plus generic products.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now